RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
The conversation is a humorous discussion about excessive hair growth due to using minoxidil, with suggestions of laser hair removal and comments on the appearance of the hair. Some users joke about starting finasteride treatment at a young age or being non-responders to hair loss treatments.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
The conversation discusses the potential for Verteporfin to reduce scarring, making hairline lowering surgeries more viable for men with mild hair loss. The user suggests that if scarring can be minimized, men might opt for hairline lowering instead of using grafts for other areas.
Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
The conversation discusses hair loss treatments beyond the commonly known three, focusing on separating effective treatments from myths. Dutasteride and low-dose oral Minoxidil are mentioned as having clinical evidence for increasing hair counts, but with potential side effects.
The conversation discusses the complexity of hair loss causes, suggesting that DHT sensitivity alone doesn't fully explain it. Treatments mentioned include finasteride and dutasteride.
A 22.5-year-old male is frustrated with doctors for not taking his diffuse thinning seriously. He has been using finasteride for 2.5 years, avoids topical minoxidil due to dandruff, and is hesitant about oral minoxidil due to weight and injury concerns.
Potential treatments for hair loss, including Minoxidil, finasteride, RU58841 and various upcoming pharmaceuticals, gene editing and cloning. It is suggested that a cure, if found, would be highly profitable due to the large number of people affected by hair loss globally.
The user is using a combination of 7% minoxidil, 0.2% finasteride, 0.5mg finasteride, RU58841, and daily microneedling but is not seeing hair regrowth after 5 months. Suggestions include being patient, reducing microneedling frequency, considering oral minoxidil, and possibly switching to dutasteride if no improvement after a year.
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
Treating androgenic alopecia with minoxidil, finasteride, and antiandrogens, alongside exercise, cryotherapy, and natural substances to stimulate cold receptors for better hair growth. The method focuses on enhancing treatment effectiveness by considering environmental and behavioral factors and the role of cold receptors and muscle stress.
The conversation is about a user experiencing increased hair loss after altering their treatment routine of oral dutasteride and topical minoxidil. The dermatologist emphasized the importance of diet and vitamins, but the user is skeptical given their healthy lifestyle.
The conversation discusses the correct method of microneedling for hair loss, questioning whether it should be done on areas with long hair without risking hair damage, and if it's necessary for improving blood flow to existing hair. No specific treatments were mentioned.
Exosome stemcell treatment for hair loss, which is expensive and reportedly effective, but its popularity has declined. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
The conversation is about someone seeking advice on choosing between stemcell therapy and PRP for treating hair loss, asking for personal results, side effects, overall satisfaction, and recommendations from others.
A stemcell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
Exosome hair therapy involves injecting stemcell-derived exosomes into the scalp to boost hair follicle regeneration and repair. Exosomes, which are not stem cells but products of them, contain bioactive chemicals and specific growth factors that promote new blood vessel formation, increase cell proliferation, reduce inflammation, and improve tissue repair, all crucial for hair health.
The conversation discusses the benefits of combining scalp stemcell treatments and exohealer with RF microneedling before a hair transplant. The original poster recommends these treatments for better results.
The conversation discusses hair regrowth treatments, including stemcell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
TGF-B affects hair growth, both causing stemcell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
A 34-year-old underwent a hair transplant with 5,250 grafts, stemcell therapy, and PRP at Dr. Hakan Clinic in Istanbul, without using Minoxidil or Finasteride. Despite initial concerns about the hairline design, the user is optimistic about the results and plans to update progress over time.
The user stabilized hair loss with oral finasteride, dutasteride, and topical minoxidil, and underwent a stemcell and PRP procedure. Recent increased hair shedding may be due to restarting dermarolling, affecting minoxidil absorption, or the waning effects of the stemcell treatment.
User asks where to purchase exosomes/AAPE for microneedling hair loss treatment. Links to research on hair regeneration therapy, stemcell therapy, exosome therapy, and dermal exosomes provided.
Minoxidil, PRP, low-level light therapy, stemcell therapy, mesotherapy, Acell, and microneedling are discussed as treatments for thickening fine hairs in NW5 hair loss sufferers. A hair transplant may be necessary for significant improvement.
The user shared their positive experience with a hair transplant in South Korea, highlighting thorough consultations, consistent medical team involvement, and reasonable pricing. They noted good growth and natural-looking results after several months, with stemcell PRP treatment included to support graft survival.